A PLATFORM OF INNOVATIVE PRODUCTS

In addition, patients had significant quality of life improvements, with less fatigue, anxiety, irritability, affective lability, disturbance to waking, daytime drowsiness, headache, and nocturnal sleep.

NA-831 was well-tolerated with no adverse events or concerning safety signals. In addition, there was a significant improvement in the memory test performance for the Alzheimer’s patients in the study who were administered NA-831 compared to placebo.

NA-831 showed a significant improvement for patients with mild and moderate AD with the ADAS-Cog score changed of an average of 4.1 as compared to the placebo after 24 weeks of treatment . The Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) showed 82.1% patients improved.

The topline results of the Phase 2A of NA-831 was presented at the Alzheimer Association International Conference (AAIC) - July 25, 2018 in Chicago and the follow-up results were given at the AAIC, July 17, 2019 in Los Angeles.

UPCOMING PHASE 3 CLINICAL TRIALS OF NA-841

Neuroactiva plans to conduct two Phase 3 programs for NA-831:

(1) The COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.

(2) The PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.

These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.

Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.

The Phase 3 clinical trials of NA-831 have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.

VINEUROCIN™ (NA-704™ )

Vineurocin (NA704) can be shown to modulate the aging process in humans. NA-704 can also regulate cell growth and development, especially in nerve cells, as well as cellular DNA synthesis.

In preclinical studies, NA-704 is able to stimulate regeneration of neurons, outgrowth of electrically active fibers, restoration of neuronal function, and reduction of muscular spasticity.

NA-704™ exhibits neuroprotection and neurogenesis, which has been demonstrated as a strong candidate for treatment of Alzheimer’s disease and other neurological disorders. NA-704 is to be administered intravenously once a week, per prescription of a qualified physician.

NA-704 has excellent proof of safety in Phase 1 clinical trial. Phase 2 of NA-704 will start in 2020.

MICROS™ CONTROLLED RELEASE DRUG DELEIVERY SYSTEM

The MICROS™ Infusion System has been approved by the United Stated Food and Drug Administration (FDA) for marketing in the USA.

The MICROS Infusion System is a disposable infusion system designed for the intravenous administration of injectable drugs. There are more than 100 injectable drugs can be used with the MICROS for treatment of infectious diseases, cancer chemotherapy and cardiovascular diseases and neurological diseases.

The MICROS can be prefilled with NA-704 for controlled release of the injectable medication for treatment of Alzheimer's disease and Multiple Sclerosis.

MICROS is a controlled released infusion system that can be prefilled with a customized dosage of NA-704 to be available as a premixed and ready to use package.

The NA-704/MICROS infusion system offers an accurate intravenous dosage and is ready to be administered to the patient in a convenient and comfortable setting at home for Alzheimer patients.

MICROS™ FEATURES & BENEFITS:

* An advanced infusion system for more than 100 injectable drug formulations for treatment of infectious diseases, cancer chemotherapy, cardiovascular and neurological diseases.

* The MICROS™ is made with a patented nano-membrane, which provides excellent accuracy and high efficiency exceeding 97%.

* Ensure aseptic system with built-in nanoscale membrane (50 nanometers) eliminating particulates, bacteria, and endotoxin.

* A unique disposable infusion system that can be used for multiple doses up to 3 days.

* A cost-effective drug delivery system that can save a 300 bed hospital more than $200,000 per year in intravenous products.

For more information about the MICROS™ Infusion System, please visit the MICROS webpage.

For further information about our platform of productrs, please contact us by completing an Online Contact Form. Thank you.